Diabetes and obesity
Tirzepatide reduced BMI in adolescents with obesity in a 72-week trial
At 72 weeks, adolescents taking tirzepatide had an 18.5% mean BMI reduction, compared with a 0.5% increase with placebo.

Once-weekly tirzepatide reduced BMI more than placebo in the phase III SURMOUNT-ADOLESCENTS trial, according to results presented at ObesityWeek and published in JAMA. The trial enrolled 160 adolescents with obesity or overweight and at least one weight-related complication. Participants received tirzepatide or placebo for 72 weeks alongside a healthy lifestyle intervention.
At week 72, mean BMI fell 18.5% with tirzepatide and increased 0.5% with placebo. A BMI reduction of at least 20% occurred in 48.1% of participants taking tirzepatide and 7.9% taking placebo. BMI fell below the 95th percentile for age and sex in 53.5% and 7.1%, respectively.
Gastrointestinal events were the most common adverse events, occurring in 81.5% of the tirzepatide group and 54.9% of the placebo group. Most were mild to moderate. An accompanying editorial urged clinicians to individualize dose increases based on patients’ responses and adverse effects.


